Clinical implications of monitoring nivolumab immunokinetics in non–small cell lung cancer patients-Reference-Cited by-同舟云学术

Clinical implications of monitoring nivolumab immunokinetics in non–small cell lung cancer patients

Published:2018-10-04 Issue:19 Volume:3 Page:
ISSN:2379-3708
Container-title:JCI Insight
language:en
Short-container-title:

Author:

Osa Akio,Uenami Takeshi,Koyama Shohei,Fujimoto Kosuke,Okuzaki Daisuke^ORCID,Takimoto Takayuki,Hirata Haruhiko,Yano Yukihiro^ORCID,Yokota Soichiro,Kinehara Yuhei,Naito Yujiro,Otsuka Tomoyuki,Kanazu Masaki^ORCID,Kuroyama Muneyoshi,Hamaguchi Masanari,Koba Taro,Futami Yu,Ishijima Mikako,Suga Yasuhiko,Akazawa Yuki,Machiyama Hirotomo,Iwahori Kota,Takamatsu Hyota,Nagatomo Izumi,Takeda Yoshito,Kida Hiroshi,Akbay Esra A.,Hammerman Peter S.,Wong Kwok-kin,Dranoff Glenn,Mori Masahide,Kijima Takashi,Kumanogoh Atsushi

Funder

JSPS

AMED-Core Research for Evolutional Science and Technology

AMED

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://insight.jci.org/articles/view/59125/files/pdf

Reference42 articles.

1. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

2. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

3. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

4. Lopes G, et al. Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: open-label, phase 3 KEYNOTE-042 study. J Clin Oncol. 2018:36(suppl; abstr LBA4). https://meetinglibrary.asco.org/record/165950/abstract Accessed September 25, 2018

5. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Cited by 176 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical characteristics, treatment, and outcomes of nivolumab induced immune thrombocytopenia;Investigational New Drugs;2024-09-12

2. Interstitial Pneumonitis Following Sequential Administration of Programmed Death-1/Programmed Death-Ligand1 Inhibitors and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors For Non-Small Cell Lung Cancer: A Matched‐Pair Cohort Study Using a Nationwide Inpatient Database;Clinical Lung Cancer;2024-09

3. Clinical characteristics, treatment, and outcomes of pembrolizumab-induced uveitis;Investigational New Drugs;2024-08-14

4. Efficacy and Safety of Sorafenib or Lenvatinib for Advanced Hepatocellular Carcinoma after Failure of First-Line Atezolizumab Plus Bevacizumab: A Systematic Review and Meta-Analysis;Cancers;2024-08-10

5. Enhancement of Tumor Antigen-specific T-cell Responses by Immune Checkpoint Blockade in Human Papillomavirus-related Head and Neck Squamous Cell Carcinoma;Anticancer Research;2024-06-26